Hemolysis, Hereditary
Conditions
Keywords
Hemolysis in Patients with Hereditary Spherocytosis, with documented family history of HS., spherocyte morphology,, splenomegaly and non-immune mediated hemolysis.
Brief summary
In the present study the investigators are going to explore the oxidative status of HS-RBC and its contribution to hemolysis
Detailed description
The oxidative status of cells, which is determined by the balance between pro-oxidants, such as the reactive oxygen species (ROS), and antioxidants, is a major regulator of cellular functions. Impaired balance between pro- and antioxidants causes oxidative stress which may result in oxidation of proteins, lipids and DNA with the final outcome of premature cell aging and apoptosis \[1,2\]. Oxidatively stressed red blood cell (RBC) have been observed in various congenital and acquired hemolytic anemias, including thalassemia, sickle cell anemia, congenital dyserythropoietic anemia, G6PD deficiency and paroxysmal nocturnal hemoglobinuria (PNH) as well as in myelodysplastic syndrome (MDS). Although the primary etiology is different in these anemias, oxidative stress mediates several of their pathologies, mainly hemolysis \[3\]. Hereditary Spherocytosis (HS) is a genetic disorder of the RBC skeleton with primary deficiency in spectrin, ankyrin-1, band 3 or protein 4.2 associated with chronic hemolytic anemia \[4\]. Secondary protein deficiencies resulting from oxidative stress are often observed and may be involved in the clinical manifestations of the disease \[5\].
Interventions
Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
Sponsors
Wolfson Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* patients \> 5 years * with documented family history of HS * patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
Exclusion criteria
* non
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC | year | ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC following incubation with with 100 μM 2'-7'-dichlorofluorescin diacetate, 40 μM \[1-(4-chloromercuryphenyl-azo-2-naphthol)\] and fluor-DHPE, respectively for ROS \[8\] and with mercury orange for GSH \[9\]. After being washed twice, the cells will be resuspended in PBS and analyzed by flow cytometry . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hemolysis | year | Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) |
Countries
Israel
Contacts
Primary ContactGhoti Hossam, doctor
Outcome results
None listed